T

Tevogen Bio Holdings Inc
NASDAQ:TVGN

Watchlist Manager
Tevogen Bio Holdings Inc
NASDAQ:TVGN
Watchlist
Price: 0.364 USD 9.97% Market Closed
Market Cap: 72.3m USD

Tevogen Bio Holdings Inc
Common Stock

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Tevogen Bio Holdings Inc
Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
T
Tevogen Bio Holdings Inc
NASDAQ:TVGN
Common Stock
$356.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Common Stock
$18m
CAGR 3-Years
0%
CAGR 5-Years
0%
CAGR 10-Years
1%
Gilead Sciences Inc
NASDAQ:GILD
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Common Stock
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Common Stock
$101.8k
CAGR 3-Years
1%
CAGR 5-Years
0%
CAGR 10-Years
-1%
No Stocks Found

Tevogen Bio Holdings Inc
Glance View

Market Cap
72.3m USD
Industry
Biotechnology

Tevogen Bio Holdings Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Warren, New Jersey. The company went IPO on 2021-11-04. Tevogen Bio Holdings Inc. is a clinical-stage specialty immunotherapy company. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, is an off-the-shelf, allogeneic cytotoxic CD8+ T cell therapy designed to fill a critical gap in COVID-19 therapeutic solutions for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of Long COVID. In addition to TVGN 489, it has several product candidates under early-stage development. The firm is developing Epstein-Barr virus (EBV) specific CTLs for potential use in multiple sclerosis (MS) and EBV-associated lymphomas. Its TVGN 601 is being developed for MS, and its TVGN 930 is being developed for EBV-associated lymphomas.

TVGN Intrinsic Value
Not Available
T

See Also

What is Tevogen Bio Holdings Inc's Common Stock?
Common Stock
356.9m USD

Based on the financial report for Dec 31, 2022, Tevogen Bio Holdings Inc's Common Stock amounts to 356.9m USD.

What is Tevogen Bio Holdings Inc's Common Stock growth rate?
Common Stock CAGR 1Y
1%

Over the last year, the Common Stock growth was 1%.

Back to Top